Pricop Catalin, Șerban Dragomir Nicolae, Șerban Ionela Lacramioara, Cumpanas Alin Adrian, Puia Dragoș
Department of Urology, "Gr. T. Popa" University of Medicine and Pharmacy, "C. I. Parhon" Hospital, Iasi, Romania.
Department of Physiology, "Gr. T. Popa" University of Medicine and Pharmacy, Iasi, Romania.
Wideochir Inne Tech Maloinwazyjne. 2020 Dec;15(4):602-607. doi: 10.5114/wiitm.2020.92307. Epub 2020 Jan 16.
Different antagonists of adrenergic receptors (-blockers) have been used as medical expulsive treatment (MET) after extracorporeal shock wave lithotripsy (ESWL).
To retrospectively evaluate the expulsion rate of fragments after extracorporeal shock wave lithotripsy performed for single ureteral stones followed by different medical expulsive treatments.
We retrospectively analyzed stone expulsion rates of 190 patients treated by shock wave lithotripsy (SWL) for single, 5 to 10 mm, symptomatic and uncomplicated distal ureteric stones, treated with tamsulosin 0.4 mg, silodosin 8 mg or silodosin 4 mg as MET. Beside the stone-free rate after 4 weeks of treatment, we also investigated the pain intensity using the visual analogue scale (VAS), adverse events induced by the medication, safety of drug administration and the reasons for possible early treatment discontinuation.
Silodosin 8 mg and tamsulosin 0.4 mg have similar results in terms of stone-free rate. For silodosin 4 mg the stone-free rate was significantly lower than for the previous two drugs. In patients treated with silodosin 4 mg the VAS was significantly higher than in patients treated with silodosin 8 mg or tamsulosin 0.4 mg, for all the follow-up visits.
Alpha-blocker treatment after ESWL with silodosin 8 mg offers a similar stone-free rate compared with tamsulosin 0.4 mg, being well tolerated. A lower dose of silodosin (4 mg) has significantly poor results, irrespective of ureteric stone size, with more frequent renal colic and severe pain.
不同的肾上腺素能受体拮抗剂(β受体阻滞剂)已被用于体外冲击波碎石术(ESWL)后的药物排石治疗(MET)。
回顾性评估针对单一输尿管结石进行体外冲击波碎石术后采用不同药物排石治疗的结石碎片排出率。
我们回顾性分析了190例接受冲击波碎石术(SWL)治疗单一、5至10毫米、有症状且无并发症的远端输尿管结石患者的结石排出率,这些患者分别接受坦索罗辛0.4毫克、西洛多辛8毫克或西洛多辛4毫克作为药物排石治疗。除了治疗4周后的无石率,我们还使用视觉模拟量表(VAS)调查疼痛强度、药物引起的不良事件、药物给药安全性以及可能提前停药的原因。
西洛多辛8毫克和坦索罗辛0.4毫克在无石率方面结果相似。西洛多辛4毫克的无石率显著低于前两种药物。在所有随访中,接受西洛多辛4毫克治疗的患者的VAS显著高于接受西洛多辛8毫克或坦索罗辛0.4毫克治疗的患者。
ESWL后使用8毫克西洛多辛进行α受体阻滞剂治疗与0.4毫克坦索罗辛相比,无石率相似,耐受性良好。较低剂量的西洛多辛(4毫克)无论输尿管结石大小,结果均显著较差,肾绞痛和剧痛更频繁。